Drug Pipeline

Cobimetinib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
15
Active Studies
3
Recruiting
2
Phase 3
10
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages…		 Primary endpoint(s) modified
Active Studies by Phase
Phase 3
1
Phase 2/3
1
Phase 2
8
Phase 1/2
1
Phase 1
3
Early Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT03768063 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd… Cancer Active, Not Recruiting
Phase 2/3
NCT03178552 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments… Non-Small Cell Lung Cancer Active, Not Recruiting
Phase 2
NCT06440850 Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated… Thyroid Gland Follicular Carcinoma Recruiting
NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages… Non-small Cell Lung Cancer Recruiting
NCT03181100 Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly… Metastatic Thyroid Gland Carcinoma Active, Not Recruiting
NCT03175432 Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With… BRAF V600 Wild Type Active, Not Recruiting
NCT04409639 Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations Chronic Myelomonocytic Leukemia (CMML) Active, Not Recruiting
NCT04931342 A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With… Ovarian Cancer Active, Not Recruiting
NCT03202316 Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant… Recurrent Breast Inflammatory Carcinoma Active, Not Recruiting
NCT03224767 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive… BRAF V600E Mutation Present Active, Not Recruiting
Phase 1/2
NCT03202940 A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged… Non-small Cell Lung Cancer Active, Not Recruiting
Phase 1
NCT02721459 XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Melanoma Active, Not Recruiting
NCT04835805 A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in… Melanoma Active, Not Recruiting
NCT05691504 Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian… Advanced Endometrial Carcinoma Active, Not Recruiting
Early Phase 1
NCT04005690 Targeted Pathway Inhibition in Patients With Pancreatic Cancer Locally Advanced Pancreatic Ductal Adenocarcinoma Recruiting
Sponsors Running Cobimetinib Trials
M.D. Anderson Cancer Center (3) Hoffmann-La Roche (3) Genentech, Inc. (2) H. Lee Moffitt Cancer Center and Research Institute (1) Massachusetts General Hospital (1) Alliance for Clinical Trials in Oncology (1) OHSU Knight Cancer Institute (1) University of Utah (1) National Cancer Institute (NCI) (1) City of Hope Medical Center (1)
Disease Areas
Melanoma (3) Non-Small Cell Lung Cancer (NSCLC) (3) Lung Cancer (3) Ovarian Cancer (2) Pancreatic Cancer (1) Leukemia (1) Endometrial Cancer (1) Sarcoma (1)
Get alerts when Cobimetinib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free